Mortality  ||| S:0 E:10 ||| NN
in  ||| S:10 E:13 ||| IN
rheumatoid  ||| S:13 E:24 ||| JJ
arthritis  ||| S:24 E:34 ||| NN
and  ||| S:34 E:38 ||| CC
ankylosing  ||| S:38 E:49 ||| NNS
spondylitis  ||| S:49 E:61 ||| VBP
The  ||| S:61 E:65 ||| DT
rheumatic  ||| S:65 E:75 ||| JJ
diseases  ||| S:75 E:84 ||| NNS
not  ||| S:84 E:88 ||| RB
only  ||| S:88 E:93 ||| RB
bring  ||| S:93 E:99 ||| VB
pain ||| S:99 E:103 ||| NN
,  ||| S:103 E:105 ||| ,
disability  ||| S:105 E:116 ||| NN
and  ||| S:116 E:120 ||| CC
poorer  ||| S:120 E:127 ||| JJR
quality  ||| S:127 E:135 ||| NN
of  ||| S:135 E:138 ||| IN
life ||| S:138 E:142 ||| NN
,  ||| S:142 E:144 ||| ,
but  ||| S:144 E:148 ||| CC
also  ||| S:148 E:153 ||| RB
a  ||| S:153 E:155 ||| DT
premature  ||| S:155 E:165 ||| JJ
mortality  ||| S:165 E:175 ||| NN
which  ||| S:175 E:181 ||| WDT
is  ||| S:181 E:184 ||| VBZ
often  ||| S:184 E:190 ||| RB
overlooked ||| S:190 E:200 ||| VBN
.  ||| S:200 E:202 ||| .
Alongside  ||| S:202 E:212 ||| IN
mortality  ||| S:212 E:222 ||| NN
due  ||| S:222 E:226 ||| JJ
to  ||| S:226 E:229 ||| TO
the  ||| S:229 E:233 ||| DT
direct  ||| S:233 E:240 ||| JJ
complications  ||| S:240 E:254 ||| NNS
of  ||| S:254 E:257 ||| IN
disease  ||| S:257 E:265 ||| NN
comes  ||| S:265 E:271 ||| VBZ
an  ||| S:271 E:274 ||| DT
increase  ||| S:274 E:283 ||| NN
in  ||| S:283 E:286 ||| IN
deaths  ||| S:286 E:293 ||| NNS
related  ||| S:293 E:301 ||| VBN
to  ||| S:301 E:304 ||| TO
specific  ||| S:304 E:313 ||| JJ
therapies  ||| S:313 E:323 ||| NNS
and  ||| S:323 E:327 ||| CC
indirect  ||| S:327 E:336 ||| JJ
causes  ||| S:336 E:343 ||| NNS
such  ||| S:343 E:348 ||| JJ
as  ||| S:348 E:351 ||| IN
cancer  ||| S:351 E:358 ||| NN
and  ||| S:358 E:362 ||| CC
cardiovascular  ||| S:362 E:377 ||| JJ
mortality ||| S:377 E:386 ||| NN
.  ||| S:386 E:388 ||| .
By  ||| S:388 E:391 ||| IN
comparing  ||| S:391 E:401 ||| VBG
mortality  ||| S:401 E:411 ||| NN
and  ||| S:411 E:415 ||| CC
its  ||| S:415 E:419 ||| PRP$
causes  ||| S:419 E:426 ||| NNS
in  ||| S:426 E:429 ||| IN
two  ||| S:429 E:433 ||| CD
of  ||| S:433 E:436 ||| IN
the  ||| S:436 E:440 ||| DT
most  ||| S:440 E:445 ||| RBS
common  ||| S:445 E:452 ||| JJ
inflammatory  ||| S:452 E:465 ||| JJ
arthritides ||| S:465 E:476 ||| NN
,  ||| S:476 E:478 ||| ,
rheumatoid  ||| S:478 E:489 ||| JJ
arthritis  ||| S:489 E:499 ||| NN
and  ||| S:499 E:503 ||| CC
ankylosing  ||| S:503 E:514 ||| JJ
spondylitis ||| S:514 E:525 ||| NN
,  ||| S:525 E:527 ||| ,
common  ||| S:527 E:534 ||| JJ
threads  ||| S:534 E:542 ||| JJ
emerge  ||| S:542 E:549 ||| NN
which  ||| S:549 E:555 ||| WDT
give  ||| S:555 E:560 ||| VBP
us  ||| S:560 E:563 ||| PRP
insight  ||| S:563 E:571 ||| VBD
into  ||| S:571 E:576 ||| IN
the  ||| S:576 E:580 ||| DT
impact  ||| S:580 E:587 ||| NN
of  ||| S:587 E:590 ||| IN
chronic  ||| S:590 E:598 ||| JJ
inflammatory  ||| S:598 E:611 ||| JJ
disease  ||| S:611 E:619 ||| NN
and  ||| S:619 E:623 ||| CC
new  ||| S:623 E:627 ||| JJ
directions  ||| S:627 E:638 ||| NNS
for  ||| S:638 E:642 ||| IN
patient  ||| S:642 E:650 ||| JJ
management ||| S:650 E:660 ||| NN
.  ||| S:660 E:662 ||| .
